ATE477819T1 - Verwendung von organischen verbindungen - Google Patents
Verwendung von organischen verbindungenInfo
- Publication number
- ATE477819T1 ATE477819T1 AT07783060T AT07783060T ATE477819T1 AT E477819 T1 ATE477819 T1 AT E477819T1 AT 07783060 T AT07783060 T AT 07783060T AT 07783060 T AT07783060 T AT 07783060T AT E477819 T1 ATE477819 T1 AT E477819T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- organic compounds
- metabolic
- dyslipdemia
- errgamma
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033307 Overweight Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 230000037080 exercise endurance Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79722806P | 2006-05-03 | 2006-05-03 | |
| PCT/US2007/067971 WO2007131005A2 (en) | 2006-05-03 | 2007-05-02 | Use of organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE477819T1 true ATE477819T1 (de) | 2010-09-15 |
Family
ID=38477124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07783060T ATE477819T1 (de) | 2006-05-03 | 2007-05-02 | Verwendung von organischen verbindungen |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090281191A1 (de) |
| EP (1) | EP2015777B1 (de) |
| JP (1) | JP2009535425A (de) |
| KR (1) | KR20090005137A (de) |
| CN (1) | CN101432024A (de) |
| AT (1) | ATE477819T1 (de) |
| AU (1) | AU2007248112A1 (de) |
| BR (1) | BRPI0711174A2 (de) |
| CA (1) | CA2649701A1 (de) |
| DE (1) | DE602007008553D1 (de) |
| MX (1) | MX2008014008A (de) |
| RU (1) | RU2008147269A (de) |
| WO (1) | WO2007131005A2 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103154246B (zh) | 2010-05-14 | 2015-11-25 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
| ES2606958T3 (es) | 2010-05-14 | 2017-03-28 | Dana-Farber Cancer Institute, Inc. | Compuestos de tienotriazolodiazepina para tratar una neoplasia |
| CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| US8962546B2 (en) * | 2011-03-01 | 2015-02-24 | Salk Institute For Biological Studies | Modulation of estrogen receptor-related receptor gamma (ERRγ) and uses therefor |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2567959B1 (de) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| WO2014205045A1 (en) * | 2013-06-18 | 2014-12-24 | Downes, Michael | Methods of treating muscular dystrophy |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
| WO2015117083A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| MX2016009974A (es) | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de diaminopirimidina bencensulfona y sus usos. |
| EP3099693A4 (de) | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Verwendungen von diazepinderivaten |
| WO2015131113A1 (en) | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
| EP3739041A1 (de) | 2014-03-27 | 2020-11-18 | The Salk Institute for Biological Studies | Zusammensetzungen und verfahren zur behandlung von typ-1-diabetes und typ-2-diabetes sowie von verwandten erkrankungen |
| RU2017104897A (ru) | 2014-08-08 | 2018-09-10 | Дана-Фарбер Кэнсер Инститьют, Инк. | Производные диазепана и их применения |
| WO2016022970A1 (en) * | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| UA122130C2 (uk) | 2014-10-27 | 2020-09-25 | Тенша Терапеутікс, Інк. | Інгібітори бромодомену |
| US10920199B2 (en) * | 2015-02-27 | 2021-02-16 | Salk Institute For Biological Studies | Reprogramming progenitor compositions and methods of use therefore |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| US11306105B2 (en) | 2015-09-11 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| WO2017053084A1 (en) * | 2015-09-25 | 2017-03-30 | Salk Institute For Biological Studies | Estrogen related receptor gamma (erry) enhances and maintains brown fat thermogenic capacity |
| CR20180336A (es) | 2015-11-25 | 2018-08-06 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos |
| EP3936610A1 (de) | 2016-05-25 | 2022-01-12 | Salk Institute for Biological Studies | Zusammensetzungen und verfahren zur organoiderzeugung und krankheitsmodellierung |
| MX2021004140A (es) | 2018-10-12 | 2021-08-05 | Salk Inst For Biological Studi | Celulas, isletas y organoides que evaden la deteccion inmunitaria y la autoinmunidad, metodos de produccion y usos de los mismos. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091006B2 (en) * | 2001-11-09 | 2006-08-15 | Dana-Farber Cancer Institute, Inc. | PGC-1β, a novel PGC-1 homologue and uses therefor |
| JPWO2004015415A1 (ja) * | 2002-08-08 | 2005-12-02 | 独立行政法人科学技術振興機構 | 薬剤スクリーニング方法 |
| US20050074765A1 (en) * | 2002-10-16 | 2005-04-07 | Blanchard Steven G. | Methods for identifying and using modulators of estrogen related receptor gamma |
| US7655756B2 (en) * | 2005-05-27 | 2010-02-02 | Johnson & Johnson Pharmaceutical Research & Development, Llc | Crystallized structure of estrogen related receptor gamma in complex with bisphenol A |
-
2007
- 2007-05-02 DE DE602007008553T patent/DE602007008553D1/de active Active
- 2007-05-02 AU AU2007248112A patent/AU2007248112A1/en not_active Abandoned
- 2007-05-02 BR BRPI0711174-6A patent/BRPI0711174A2/pt not_active IP Right Cessation
- 2007-05-02 CN CNA2007800155975A patent/CN101432024A/zh active Pending
- 2007-05-02 WO PCT/US2007/067971 patent/WO2007131005A2/en not_active Ceased
- 2007-05-02 MX MX2008014008A patent/MX2008014008A/es not_active Application Discontinuation
- 2007-05-02 RU RU2008147269/14A patent/RU2008147269A/ru not_active Application Discontinuation
- 2007-05-02 JP JP2009510039A patent/JP2009535425A/ja active Pending
- 2007-05-02 US US12/299,256 patent/US20090281191A1/en not_active Abandoned
- 2007-05-02 AT AT07783060T patent/ATE477819T1/de not_active IP Right Cessation
- 2007-05-02 KR KR1020087026812A patent/KR20090005137A/ko not_active Withdrawn
- 2007-05-02 EP EP07783060A patent/EP2015777B1/de not_active Revoked
- 2007-05-02 CA CA002649701A patent/CA2649701A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007248112A1 (en) | 2007-11-15 |
| RU2008147269A (ru) | 2010-06-10 |
| DE602007008553D1 (de) | 2010-09-30 |
| JP2009535425A (ja) | 2009-10-01 |
| CN101432024A (zh) | 2009-05-13 |
| WO2007131005A3 (en) | 2008-06-19 |
| EP2015777A2 (de) | 2009-01-21 |
| KR20090005137A (ko) | 2009-01-12 |
| WO2007131005A2 (en) | 2007-11-15 |
| BRPI0711174A2 (pt) | 2011-08-23 |
| EP2015777B1 (de) | 2010-08-18 |
| MX2008014008A (es) | 2009-03-25 |
| US20090281191A1 (en) | 2009-11-12 |
| CA2649701A1 (en) | 2007-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602007008553D1 (de) | Verwendung von organischen verbindungen | |
| IL202269A0 (en) | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes | |
| CY1118611T1 (el) | Συνδυασμοι που περιεχουν παραγωγα της 6-βενζυλο-φαινυλο-2-θειοτετραϋδροπυραν-3,4,5-τριολης ως αναστολεις των συμμεταφορεων 1 και 2 νατριου-γλυκοζης για να χρησιμοποιηθουν σε διαβητικους ασθενεις | |
| MX2009006709A (es) | Tratamiento de enfermedades relacionadas con il-1beta. | |
| EP2560660A4 (de) | Auf chemosensorischen rezeptorliganden basierende therapien | |
| CL2007001030A1 (es) | Compuestos derivados de heterociclilguanidina; y composicion farmaceutica, util para el tratamiento de la enfermedad de alzheimer, demencia senil y demencia asociada a enfermedad de parkinson entre otras. | |
| CL2007003264A1 (es) | Compuestos derivados de 1,4-benzotiepina 1,1-dioxido sustituidos con radicales bencilo; producto farmaceutico; y uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del sn | |
| EA201000050A1 (ru) | Замещенные бициклолактамные соединения | |
| WO2012021629A3 (en) | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | |
| CL2007003262A1 (es) | Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades. | |
| WO2007104789A3 (en) | Amylin derivatives | |
| HK1203830A1 (en) | Compositions and methods for treating metabolic disorders | |
| MX2009012285A (es) | Inhibidores de diacilglicerol aciltransferasa. | |
| WO2008103354A3 (en) | Modulators of acetyl-coenzyme a carboxylase and methods of use thereof | |
| IL187005A0 (en) | Diacylglycerol acyltransferase inhibitors | |
| CL2008001960A1 (es) | Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide. | |
| DK2114933T3 (da) | Piperidin-GPCR-agonister | |
| WO2008097428A3 (en) | Compounds and compositions as modulators of gpr119 activity | |
| MX2014008190A (es) | Composiciones de biguanida y métodos para tratar transtornos metabólicos. | |
| EA200870470A1 (ru) | Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1 | |
| CL2009000402A1 (es) | Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras. | |
| WO2009121939A3 (en) | C-aryl glycoside compounds for the treatment of diabetes and obesity | |
| CL2007002427A1 (es) | Compuestos derivados heterociclicos, inhibidores de metaloproteinasa de matriz; proceso de preparacion; composicion farmaceutica, util para el tratamiento o profilaxis de enfermedades inflamatorias o desordenes autoinmunes. | |
| DOP2005000025A (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
| EP2579876A4 (de) | Therapeutische behandlung des stoffwechselsyndroms, typ-2-diabetes, obesität oder prädiabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |